Page 65 - Clinical Development News Today

Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities Review includes differentiated mechanisms of action including tumor-localized activation, avidity-driven selectivity and novel SWITCH-DARPin approach ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech com

BERGEN, Norway, Nov. 14, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage...

A small molecule, oral targeted therapy for adults with metastatic colorectal cancer (CRC) has been approved by the US Food and Drug Administration (FDA).

BERGEN, Norway, Nov. 14, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage...

Owlstone Medical's exegenous volatile organic compound (EVOC) breath test can reveal signs of liver cirrhosis and portal hypertension, a study has found.

The first-ever national cancer innovation accelerator initiative has been given public support from the White House.

The drug target for the Duchenne program is AAK1, a protein kinase in the Notch pathway, which the Company discovered can be modulated to enable muscle…

Net Revenue Rises as Company Advances with UGN-102 Clinical Development

Cancer remains one of the most pressing public health challenges worldwide, affecting millions of lives and compounding economic burdens along the way.  ...

Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October...